1-3 of 3
Alejandro Daniel Ricart, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Nathalie A. Johnson, John A. Radford, MD, Vincent Ribrag, MD, Daniel Molin, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian von Tresckow, MD, Margaret A. Shipp, MD, Eric Gustafson, PhD, Yinghua Zhang, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Robert W Chen, MD
Journal: Blood
Blood (2016) 128 (22): 1107.
https://doi.org/10.1182/blood.V128.22.1107.1107
Published: 2016
Journal Articles

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Pier Luigi Zinzani, MD PhD, John Kuruvilla, MD, Ying Zhu, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 1108.
https://doi.org/10.1182/blood.V128.22.1108.1108
Published: 2016
Journal Articles

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Changxia Shao, PhD, Jinan Liu, PhD, Wei Zhou, PhD, Monika Kumar Raut, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM
Journal: Blood
Blood (2016) 128 (22): 2377.
https://doi.org/10.1182/blood.V128.22.2377.2377
Published: 2016